LINTONPHARM
27.5.2022 15:02:13 CEST | Business Wire | Press release
LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Abstract Number：
e16102
Abstract Title：
Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.
The abstract is about the cohort A, stage I of the ongoing global phase Ⅲ trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis (clinicaltrials.gov: NCT04222114). Worldwide, GC is one of the most common cancers, contributing to more than 1 million cases per year and 5.6% of all cancer diagnoses [1] . Approximately 50% of the advanced GC patients will develop peritoneal metastasis after radical resection, along with malignant ascites in most cases. Furthermore, peritoneal metastasis is associated with poor prognosis and quality of life compared with metastasis to other organs [2] . Peritoneal metastasis is treated with systemic therapies. The estimated survival period for the patients who fail to respond to third-line therapy is limited to only 2.3-2.4 months according to multiple RCTs.
In our study, 9 GC patients with peritoneal metastasis (33% had failed third-line therapy) were treated with Catumaxomab, the median overall survival was 3.4 months, with remarkable ascites regression. Catumaxomab as an T cell engaging immunotherapy has showed promising early efficacy signals.
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. It is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. Currently, Catumaxomab is being evaluated in clinical trials for both advanced gastric cancer (NCT04222114) and non-muscle invasive bladder cancer (NCT04799847).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. For more information, please visit www.lintonpharm.com
Reference
1. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/
2. Jennifer L.L. & Travis E.G. Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis. World J Gastrointest Oncol 2018 October 15; 10(10): 282-289.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Organigram Global Accelerates Integration of Sanity Group Under Unified Global Operating Structure20.8.2026 12:00:00 CEST | Press release
Leadership, operations and market development aligned across a global platform connecting Canada with Germany and other priority international markets Sanity Group integration marks the next phase of Organigram’s global growth strategy Finn Age Hänsel appointed President, Rest of World & Chief Strategy Officer Adrian Frenzel appointed Global Chief Operating Officer Tim Emberg to continue as President, Canada Organigram’s integrated supply and commercial network will span Canada, Germany, Switzerland, Poland, Czechia, the United Kingdom and Australia Sanity contributed approximately CAD$40 million to consolidated net revenue in Organigram’s most recent quarter, representing over 35% of net revenue, and was accretive to Adjusted EBITDA Sanity has demonstrated a strong growth trajectory, with quarterly revenue increasing 34% since December 31, 2025 to €25.5 million Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram” or the “Company”) today announced an important milestone in its
NTT DATA and Palo Alto Networks Sign Global Strategic Alliance to Accelerate Secure AI Transformation20.8.2026 12:00:00 CEST | Press release
First-of-its-kind global alliance combines AI-powered security innovation with enterprise-scale consulting and managed services Helps organizations navigate Frontier AI with integrated governance, threat intelligence and cybersecurity expertise Backed by co-innovation, shared engineering, coordinated global delivery and more than 2,000 Palo Alto Networks-certified professionals NTT DATA, a global leader in AI, digital business and technology services, and Palo Alto Networks (NASDAQ: PANW) today announced a multi-year strategic alliance designed to help organizations securely adopt AI, modernize cybersecurity, simplify complex technology environments and build cyber resilience for the AI era. As Palo Alto Networks first strategic alliance of this kind with a global systems integrator, the agreement, which targets $1 billion in joint business by the end of three years (2029), combines Palo Alto Networks AI-powered cybersecurity platforms with NTT DATA's consulting, engineering and manage
Packaging Redesigns See 4% Average Volume Lift, NIQ Finds20.8.2026 12:00:00 CEST | Press release
Liquid I.V., Hostess, Back to Nature, and five other brands named 2026 NIQ Design Impact Award winners NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today named the winners of its ninth annual Design Impact Awards, recognizing eight package redesigns that combined stronger shopper experiences with measurable commercial performance. Across nearly a decade of NIQ Design Impact Award winners, recognized redesigns have been associated with an average volume increase of approximately 4%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819712595/en/ NIQ Design Impact Awards 2026 The 2026 NIQ Design Impact Award Winners*:Aval French Cider (Parent Company: Aval Cider; Country: USA) Liquid I.V. (Parent Company: Unilever; Country: USA) Root & Splendor (Parent Company: Root & Splendor; Country: USA) Hostess Cakes (Parent Company: The J.M. Smucker Company; Country: USA) Back to Nature (Parent Company: Barilla Group;
BOCHK and Ant International Forge Strategic Partnership to Enhance Cross-border Payment Connectivity and Innovative Corporate Financial Service Solutions Through Fintech20.8.2026 09:00:00 CEST | Press release
Ant International and Bank of China (Hong Kong) (“BOCHK”) announced that the two parties have forged a strategic partnership. Leveraging BOCHK’s banking strengths and Ant International’s leading fintech and AI technologies, the two parties seek to explore the frontier of AI-driven innovative financial services, empower real-time treasury management and cross-border payments, deliver efficient and intelligent liquidity management and financial service solutions for global enterprises, while continuously enhancing financial services for small and medium-sized enterprises (“SMEs”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260820387312/en/ From left to right: Kelvin Li, General Manager of Platform Tech and Senior Vice President of Ant International, Eric Jing, Chairman of Ant International, Sun Yu, Vice Chairman and Chief Executive of BOCHK, and Wang Huabin, Deputy Chief Executive of BOCHK Sun Yu, Vice Chairman and Chief E
BOCHK and Ant International Forge Strategic Partnership to Enhance Cross-border Payment Connectivity and Innovative Corporate Financial Service Solutions Through Fintech20.8.2026 08:00:00 CEST | Press release
Ant International and Bank of China (Hong Kong) (“BOCHK”) announced that the two parties have forged a strategic partnership. Leveraging BOCHK’s banking strengths and Ant International’s leading fintech and AI technologies, the two parties seek to explore the frontier of AI-driven innovative financial services, empower real-time treasury management and cross-border payments, deliver efficient and intelligent liquidity management and financial service solutions for global enterprises, while continuously enhancing financial services for small and medium-sized enterprises (“SMEs”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819555366/en/ From left to right: Kelvin Li, General Manager of Platform Tech and Senior Vice President of Ant International, Eric Jing, Chairman of Ant International, Sun Yu, Vice Chairman and Chief Executive of BOCHK, and Wang Huabin, Deputy Chief Executive of BOCHK Sun Yu, Vice Chairman and Chief E
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom